RESUMEN
BACKGROUND: Humoral immune responses against proteins of asexual blood-stage malaria parasites have been associated with clinical immunity. However, variations in the antibody-driven responses may be associated with a genetic component of the human host. The objective of the present study was to evaluate the influence of co-stimulatory molecule gene polymorphisms of the immune system on the magnitude of the humoral immune response against a Plasmodium vivax vaccine candidate antigen. METHODS: Polymorphisms in the CD28, CTLA4, ICOS, CD40, CD86 and BLYS genes of 178 subjects infected with P. vivax in an endemic area of the Brazilian Amazon were genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The levels of IgM, total IgG and IgG subclasses specific for ICB2-5, i.e., the N-terminal portion of P. vivax merozoite surface protein 1 (PvMSP-1), were determined by enzyme-linked immuno assay. The associations between the polymorphisms and the antibody response were assessed by means of logistic regression models. RESULTS: After correcting for multiple testing, the IgG1 levels were significantly higher in individuals recessive for the single nucleotide polymorphism rs3116496 in CD28 (p = 0.00004). Furthermore, the interaction between CD28 rs35593994 and BLYS rs9514828 had an influence on the IgM levels (p = 0.0009). CONCLUSIONS: The results of the present study support the hypothesis that polymorphisms in the genes of co-stimulatory components of the immune system can contribute to a natural antibody-driven response against P. vivax antigens.
Asunto(s)
Antígenos de Protozoos/inmunología , Inmunoglobulina G/sangre , Inmunoglobulina M/sangre , Factores Inmunológicos/genética , Proteína 1 de Superficie de Merozoito/inmunología , Plasmodium vivax/inmunología , Polimorfismo Genético , Adolescente , Adulto , Anciano , Anticuerpos Antiprotozoarios/sangre , Brasil , Estudios Transversales , Femenino , Técnicas de Genotipaje , Humanos , Inmunogenética , Masculino , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa , Polimorfismo de Longitud del Fragmento de Restricción , Adulto JovenRESUMEN
Native type I heat-labile toxins (LTs) produced by enterotoxigenic Escherichia coli (ETEC) strains exert strong adjuvant effects on both antibody and T cell responses to soluble and particulate antigens following co-administration via mucosal routes. However, inherent enterotoxicity and neurotoxicity (following intra-nasal delivery) had reduced the interest in the use of these toxins as mucosal adjuvants. LTs can also behave as powerful and safe adjuvants following delivery via parenteral routes, particularly for activation of cytotoxic lymphocytes. In the present study, we evaluated the adjuvant effects of a new natural LT polymorphic form (LT2), after delivery via intradermal (i.d.) and subcutaneous (s.c.) routes, with regard to both antibody and T cell responses. A recombinant HIV-1 p24 protein was employed as a model antigen for determination of antigen-specific immune responses while the reference LT (LT1), produced by the ETEC H10407 strain, and a non-toxigenic LT form (LTK63) were employed as previously characterized LT types. LT-treated mice submitted to a four dose-base immunization regimen elicited similar p24-specific serum IgG responses and CD4(+) T cell activation. Nonetheless, mice immunized with LT1 or LT2 induced higher numbers of antigen-specific CD8(+) T cells and in vivo cytotoxic responses compared to mice immunized with the non-toxic LT derivative. These effects were correlated with stronger activation of local dendritic cell populations. In addition, mice immunized with LT1 and LT2, but not with LTK63, via s.c. or i.d. routes developed local inflammatory reactions. Altogether, the present results confirmed that the two most prevalent natural polymorphic LT variants (LT1 or LT2) display similar and strong adjuvant effects for subunit vaccines administered via i.d. or s.c. routes.
RESUMEN
Pneumococcal infections impose a large burden of disease on the human population, mainly in developing countries, and the current pneumococcal vaccines offer serotype-specific protection, but do not cover all pathogenic strains, leaving populations vulnerable to disease caused by non-vaccine serotypes. The pneumococcal whole cell vaccine is a low-cost strategy based on non-capsular antigens common to all strains, inducing serotype-independent immunity. Therefore, we developed the process for the cGMP production of this cellular vaccine. Initially, three engineering runs and two cGMP runs were performed in 60-L bioreactors, demonstrating the consistency of the production process, as evaluated by the growth curves, glucose consumption and metabolite formation (lactate and acetate). Cell recovery by tangential filtration was 92 ± 13 %. We optimized the conditions for beta-propiolactone (BPL) inactivation of the bacterial suspensions, establishing a maximum cell density of OD600 between 27 and 30, with a BPL concentration of 1:4000 (v/v) at 150 rpm and 4 °C for 30 h. BPL was hydrolyzed by heating for 2h at 37 °C. The criteria and methods for quality control were defined using the engineering runs and the cGMP Lots passed all specifications. cGMP vaccine Lots displayed high potency, inducing between 80 and 90% survival in immunized mice when challenged with virulent pneumococci. Sera from mice immunized with the cGMP Lots recognized several pneumococcal proteins in the extract of encapsulated strains by Western blot. The cGMP whole cell antigen bulk and whole cell vaccine product lots were shown to be stable for up to 12 and 18 months, respectively, based upon survival assays following i.p. challenge. Our results show the consistency and stability of the cGMP whole cell pneumococcal vaccine lots and demonstrate the feasibility of production in a developing country setting.
Asunto(s)
Reactores Biológicos , Infecciones Neumocócicas/prevención & control , Vacunas Neumococicas/biosíntesis , Propiolactona/farmacología , Animales , Anticuerpos Antibacterianos/sangre , Femenino , Fermentación , Inmunoglobulina G/sangre , Ratones , Ratones Endogámicos BALB C , Viabilidad Microbiana , Vacunas Neumococicas/inmunología , Control de CalidadRESUMEN
The human malaria is widely distributed in the Middle East, Asia, the western Pacific, and Central and South America. Plasmodium vivax started to have the attention of many researchers since it is causing diseases to millions of people and several reports of severe malaria cases have been noticed in the last few years. The lack of in vitro cultures for P. vivax represents a major delay in developing a functional malaria vaccine. One of the major candidates to antimalarial vaccine is the merozoite surface protein-1 (MSP1), which is expressed abundantly on the merozoite surface and capable of activating the host protective immunity. Studies have shown that MSP-1 possesses highly immunogenic fragments, capable of generating immune response and protection in natural infection in endemic regions. This paper shows humoral immune response to different proteins of PvMSP1 and the statement of N-terminal to be added to the list of potential candidates for malaria vivax vaccine.
Asunto(s)
Vacunas contra la Malaria/inmunología , Proteína 1 de Superficie de Merozoito/inmunología , Plasmodium vivax/inmunología , Dominios y Motivos de Interacción de Proteínas/inmunología , Vacunas de Subunidad/inmunología , Humanos , Malaria Vivax/prevención & control , Proteína 1 de Superficie de Merozoito/química , Proteína 1 de Superficie de Merozoito/metabolismo , Complejos Multiproteicos/química , Complejos Multiproteicos/metabolismo , Unión ProteicaRESUMEN
BACKGROUND: Plasmodium vivax has the potential to infect 2.85 billion individuals worldwide. Nevertheless, the limited number of studies investigating the immune status of individuals living in malaria-endemic areas, as well as the lack of reports investigating serological markers associated with clinical protection, has hampered development of vaccines for P. vivax. It was previously demonstrated that naturally total IgG against the N-terminus of P. vivax merozoite surface protein 1 (Pv-MSP1) was associated with reduced risk of malarial infection. METHODS: Immune response against Pv-MSP1 (N-terminus) of 313 residents of the Rio Pardo rural settlement (Amazonas State, Brazil) was evaluated in a cross-sectional and longitudinal follow up over two months (on site) wherein gold standard diagnosis by thick blood smear and rRNA gene-based nested real-time PCR were used to discriminate symptomless Plasmodium vivax-infected individuals who did not develop clinical symptoms during a 2-months from those uninfected ones or who have had acute malaria. The acquisition of antibodies against Pv-MSP1 was also evaluated as survival analysis by prospective study over a year collecting information of new malaria infections in surveillance database. RESULTS: The majority of P. vivax-infected individuals (52-67%) showed immune recognition of the N-terminus of Pv-MSP1. Interesting data on infected individuals who have not developed symptoms, total IgG levels against the N-terminus Pv-MSP1 were age-dependent and the IgG3 levels were significantly higher than levels of subjects had acute malaria or those uninfected ones. The total IgG anti ICB2-5 was detected to be an important factor of protection against new malaria vivax attacks in survival analysis in a prospective survey (p = 0.029). CONCLUSIONS: The study findings illustrate the importance of IgG3 associated to 2-months of symptomless in P. vivax infected individuals and open perspectives for the rationale of malaria vaccine designs capable to sustain high levels of IgG3 against polymorphic malaria antigens.
Asunto(s)
Anticuerpos Antiprotozoarios/sangre , Inmunoglobulina G/sangre , Malaria Vivax/inmunología , Proteína 1 de Superficie de Merozoito/inmunología , Adolescente , Adulto , Enfermedades Asintomáticas , Brasil , Niño , Preescolar , Estudios Transversales , Femenino , Humanos , Lactante , Recién Nacido , Estudios Longitudinales , Malaria Vivax/patología , Masculino , Microscopía , Parasitemia/diagnóstico , Estudios Prospectivos , Población Rural , Análisis de Supervivencia , Adulto JovenRESUMEN
Shiga-like toxin 2 (Stx2)-producing enterohemorrhagic Escherichia coli (referred to as EHEC or STEC) strainsare the primary etiologic agents of hemolytic-uremic syndrome (HUS), which leads to renal failure and highmortality rates. Expression of Stx2 is the most relevant virulence-associated factor of EHEC strains, and toxin neutralization by antigen-specific serum antibodies represents the main target for both preventive and therapeuticanti-HUS approaches. In the present report, we describe two Salmonella enterica serovar Typhimurium aroA vaccine strains expressing a nontoxic plasmid-encoded derivative of Stx2 (Stx2 AB) containing the complete nontoxic A2 subunit and the receptor binding B subunit. The two S. Typhimurium strains differ inthe expression of flagellin, the structural subunit of the flagellar shaft, which exerts strong adjuvant effects. Thevaccine strains expressed Stx2 AB, either cell bound or secreted into the extracellular environment, andshowed enhanced mouse gut colonization and high plasmid stability under both in vitro and in vivo conditions.Oral immunization of mice with three doses of the S. Typhimurium vaccine strains elicited serum anti-Stx2B(IgG) antibodies that neutralized the toxic effects of the native toxin under in vitro conditions (Vero cells) andconferred partial protection under in vivo conditions. No significant differences with respect to gut colonization or the induction of antigen-specific antibody responses were detected in mice vaccinated with flagellated versus nonflagellated bacterial strains. The present results indicate that expression of Stx2 AB by attenuated S. Typhimurium strains is an alternative vaccine approach for HUS control, but additional improvements in the immunogenicity of Stx2 toxoids are still required.
Asunto(s)
Humanos , Ratones , Células Vero/microbiología , Escherichia coli Enteropatógena/inmunología , Vacunas , Escherichia coli/crecimiento & desarrollo , Escherichia coli/aislamiento & purificación , Escherichia coli/metabolismo , Salmonella entericaRESUMEN
Shiga-like toxin 2 (Stx2)-producing enterohemorrhagic Escherichia coli (referred to as EHEC or STEC) strains are the primary etiologic agents of hemolytic-uremic syndrome (HUS), which leads to renal failure and high mortality rates. Expression of Stx2 is the most relevant virulence-associated factor of EHEC strains, and toxin neutralization by antigen-specific serum antibodies represents the main target for both preventive and therapeutic anti-HUS approaches. In the present report, we describe two Salmonella enterica serovar Typhimurium aroA vaccine strains expressing a nontoxic plasmid-encoded derivative of Stx2 (Stx2DeltaAB) containing the complete nontoxic A2 subunit and the receptor binding B subunit. The two S. Typhimurium strains differ in the expression of flagellin, the structural subunit of the flagellar shaft, which exerts strong adjuvant effects. The vaccine strains expressed Stx2DeltaAB, either cell bound or secreted into the extracellular environment, and showed enhanced mouse gut colonization and high plasmid stability under both in vitro and in vivo conditions. Oral immunization of mice with three doses of the S. Typhimurium vaccine strains elicited serum anti-Stx2B (IgG) antibodies that neutralized the toxic effects of the native toxin under in vitro conditions (Vero cells) and conferred partial protection under in vivo conditions. No significant differences with respect to gut colonization or the induction of antigen-specific antibody responses were detected in mice vaccinated with flagellated versus nonflagellated bacterial strains. The present results indicate that expression of Stx2DeltaAB by attenuated S. Typhimurium strains is an alternative vaccine approach for HUS control, but additional improvements in the immunogenicity of Stx2 toxoids are still required.
Asunto(s)
Escherichia coli Enterohemorrágica/inmunología , Infecciones por Escherichia coli/prevención & control , Vacunas contra Escherichia coli/inmunología , Vectores Genéticos , Salmonella typhimurium/genética , Toxina Shiga II/inmunología , Administración Oral , Animales , Anticuerpos Antibacterianos/sangre , Anticuerpos Neutralizantes/sangre , Antitoxinas/sangre , Chlorocebus aethiops , Creatinina/sangre , Infecciones por Escherichia coli/inmunología , Vacunas contra Escherichia coli/administración & dosificación , Vacunas contra Escherichia coli/genética , Inmunización Secundaria , Ratones , Ratones Endogámicos BALB C , Toxina Shiga II/biosíntesis , Urea/sangre , Vacunas Atenuadas/administración & dosificación , Vacunas Atenuadas/genética , Vacunas Atenuadas/inmunología , Células VeroRESUMEN
Salmonella flagellin, the flagellum structural subunit, has received particular interest as a vaccine adjuvant conferring enhanced immunogenity to soluble proteins or peptides, both for activation of antibody and cellular immune responses. In the present study, we evaluated the Salmonella enterica FliCd flagellin as a T cell vaccine adjuvant using as model the 9-mer (SYVPSAEQI) synthetic H2(d)-restricted CD8(+) T cell-specific epitope (CS(280-288)) derived from the Plasmodium yoelii circumsporozoite (CS) protein. The FliCd adjuvant effects were determined under two different conditions: (i) as recombinant flagella, expressed by orally delivered live S. Dublin vaccine strains expressing the target CS(280-288) peptide fused at the central hypervariable domain, and (ii) as purified protein in acellular vaccines in which flagellin was administered to mice either as a recombinant protein fused or admixed with the target CS(280-288) peptide. The results showed that CS(280-288)-specific cytotoxic CD8(+) T cells were primed when BALB/c mice were orally inoculated with the expressing the CS(280-288) epitope S. Dublin vaccine strain. In contrast, mice immunized with purified FliCd admixed with the CS(280-288) peptide and, to a lesser extent, fused with the target peptide developed specific cytotoxic CD8(+) T cell responses without the need of a heterologous booster immunization. The CD8(+) T cell adjuvant effects of flagellin, either fused or not with the target peptide, correlated with the in vivo activation of CD11c(+) dendritic cells. Taken together, the present results demonstrate that Salmonella flagellins are flexible adjuvant and induce adaptative immune responses when administered by different routes or vaccine formulations.
Asunto(s)
Adyuvantes Inmunológicos , Linfocitos T CD8-positivos/inmunología , Flagelina , Vacunas contra la Malaria , Malaria/inmunología , Plasmodium yoelii/inmunología , Proteínas Protozoarias , Proteínas Recombinantes de Fusión , Salmonella enterica/inmunología , Adyuvantes Inmunológicos/biosíntesis , Adyuvantes Inmunológicos/genética , Adyuvantes Inmunológicos/farmacología , Animales , Antígeno CD11c/inmunología , Células Dendríticas/inmunología , Flagelina/biosíntesis , Flagelina/genética , Flagelina/inmunología , Flagelina/farmacología , Inmunidad Celular/inmunología , Malaria/prevención & control , Vacunas contra la Malaria/genética , Vacunas contra la Malaria/inmunología , Vacunas contra la Malaria/farmacología , Ratones , Ratones Endogámicos BALB C , Proteínas Protozoarias/biosíntesis , Proteínas Protozoarias/genética , Proteínas Protozoarias/inmunología , Proteínas Protozoarias/farmacología , Proteínas Recombinantes de Fusión/biosíntesis , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/inmunología , Proteínas Recombinantes de Fusión/farmacología , Salmonella enterica/genética , Salmonella enterica/metabolismoRESUMEN
Objetivo: Verificar se a dieta, incluindo hábitos de aleitamento, a higiene bucal e os fatores sócio-econômicos podem ser considerados indicadores de risco para a cárie precoce da infância (CPI) em pré-escolares de Itatiba-SP. Material e método: A amostra foi constituída por 288 crianças, de 3 a 4 anos, que freqüentavam pré-escolas públicas do município de Itatiba-SP. Uma cirurgiã-dentista calibrada (Kappa=0,78) realizou exame físico para a determinação da presença de biofilme dentário e do índice de cárie. Para a avaliação da dieta foi empregado um diário alimentar, enquanto hábitos de aleitamento, higiene bucal, etnia, renda familiar e escolaridade materna foram avaliados por um questionário. Os dados foram analisados pelo teste qui-quadrado/exato de Fisher, seguido de regressão logística múltipla (alfa=0,05) expressa por razão de chances (odds ratio -OR). Resultados: A ingestão de açúcar na forma sólida 3 ou mais vezes ao dia (OR=4,5), a amamentação não exclusiva no peito por 12 meses ou mais (OR=2,0), a presença de biofilme dentário nos incisivos superiores (OR=3,1) e o fato de levar lanche para consumir na escola (OR=2,1), além da merenda, apresentaram associação significativa com a CPI (<0,05). Já os fatores etnia, escolaridade, renda familiar e freqüência de higiene bucal não se mostraram estatisticamente significativos (p>0,05). Conclusão: Os resultados sugerem que a exposição frequente aos açúcares na forma sólida, a presença de biofilme dentário e o fato de levar lanche para escola, principalmente os cariogênicos, são indicadores de risco expressivos para a cárie precoce da infância na população estudada.
Purpose: This study aimed to verify if the cariogenic diet, including nursing habits, the oral hygiene and the socioeconomic factors could be considered risk indicators for early childhood caries (ECC) in preschool children from Itatiba-SP. Methods: The sample was composed of 288 children, 3 to 4 years old, who attended public preschools from Itatiba-SP. Clinical examinations were conducted by one calibrated dentist (Kappa=0.78) for biofilm presence and caries index determination. For the diet evaluation, a diet chart was used, whereas the nursing habits, oral hygiene, ethnicity, family income and mothers´ level of education were evaluated by a questionnaire. Data were analyzed by chi-square/fisher´s exact test and multiple logistic regression (alfa=0.05) expressed by odds ratios (OR). Results: Sugar consumption in the solid form three or more times a day (OR=4.5), non-exclusive breast-feeding for 12 months or more (OR=2.0), presence of biofilm on the maxillary incisors (OR=3.1) and intake of snacks or drinks at school (OR=2.1), in addition to school meals were significantly associated with ECC (p<0.05). Besides, the factors ethnicity, level of education, family income and oral hygiene frequency did not show statistical significance (p>0.05). Conclusion: The results suggest that frequent exposure to solid sugar, biofilm presence and snacks as complement to school meals, particularly the cariogenic ones, are expressive risk indicators for early childhood caries in the population studied.
RESUMEN
Salmonella flagellin, the flagellum structural subunit, has received particular interest as a vaccineadjuvant conferring enhanced immunogenity to soluble proteins or peptides, both for activation of antibody and cellular immune responses. In the present study, we evaluated the Salmonella enterica FliCd flagellin as a T cell vaccine adjuvant using as model the 9-mer (SYVPSAEQI) synthetic H2d-restricted CD8+ T cell-specific epitope (CS280288) derived from the Plasmodium yoelii circumsporozoite (CS) protein. The FliCd adjuvant effects were determined under two different conditions: (i) as recombinant flagella,expressed by orally delivered live S. Dublin vaccine strains expressing the target CS280288 peptide fused at the central hypervariable domain, and (ii) as purified protein in acellular vaccines in which flagellin was administered to mice either as a recombinant protein fused or admixed with the target CS280288 peptide. The results showed that CS280288-specific cytotoxic CD8+ T cells were primed when BALB/c mice were orally inoculated with the expressing the CS280288 epitope S. Dublin vaccine strain. In contrast, mice immunized with purified FliCd admixed with the CS280288 peptide and, to a lesser extent,fused with the target peptide developed specific cytotoxic CD8+ T cell responses without the need of a heterologous booster immunization. The CD8+ T cell adjuvant effects of flagellin, either fused or not with the target peptide, correlated with the in vivo activation of CD11c+ dendritic cells. Taken together,the present results demonstrate that Salmonella flagellins are flexible adjuvant and induce adaptativeimmune responses when administered by different routes or vaccine formulations.
Asunto(s)
Humanos , Flagelina/análisis , Flagelina/inmunología , Salmonella enterica/inmunología , Vacunas , Adyuvantes Inmunológicos/administración & dosificación , Adyuvantes Inmunológicos/análisis , Linfocitos T/inmunologíaRESUMEN
Paracoccidioidomycosis (PCM) is a systemic granulomatous disease caused by the dimorphic fungus Paracoccidioides brasiliensis. Anti-PCM vaccine formulations based on the secreted fungal cell wall protein (gp43) or the derived P10 sequence containing a CD4(+) T-cell-specific epitope have shown promising results. In the present study, we evaluated new anti-PCM vaccine formulations based on the intranasal administration of P. brasiliensis gp43 or the P10 peptide in combination with the Salmonella enterica FliC flagellin, an innate immunity agonist binding specifically to the Toll-like receptor 5, in a murine model. BALB/c mice immunized with gp43 developed high-specific-serum immunoglobulin G1 responses and enhanced interleukin-4 (IL-4) and IL-10 levels. On the other hand, mice immunized with recombinant purified flagellins genetically fused with P10 at the central hypervariable domain, either flanked or not by two lysine residues, or the synthetic P10 peptide admixed with purified FliC elicited a prevailing Th1-type immune response based on lung cell-secreted type 1 cytokines. Mice immunized with gp43 and FliC and intratracheally challenged with P. brasiliensis yeast cells had increased fungal proliferation and lung tissue damage. In contrast, mice immunized with the chimeric flagellins and particularly those immunized with P10 admixed with FliC reduced P. brasiliensis growth and lung damage. Altogether, these results indicate that S. enterica FliC flagellin modulates the immune response to P. brasiliensis P10 antigen and represents a promising alternative for the generation of anti-PCM vaccines.
Asunto(s)
Antígenos Fúngicos , Flagelina , Proteínas Fúngicas , Vacunas Fúngicas , Glicoproteínas , Paracoccidioides/inmunología , Paracoccidioidomicosis/prevención & control , Péptidos , Animales , Anticuerpos Antibacterianos/sangre , Especificidad de Anticuerpos , Antígenos Fúngicos/química , Antígenos Fúngicos/genética , Antígenos Fúngicos/inmunología , Citocinas/metabolismo , Modelos Animales de Enfermedad , Flagelina/genética , Flagelina/inmunología , Flagelina/metabolismo , Proteínas Fúngicas/química , Proteínas Fúngicas/genética , Proteínas Fúngicas/inmunología , Vacunas Fúngicas/administración & dosificación , Vacunas Fúngicas/genética , Vacunas Fúngicas/inmunología , Glicoproteínas/química , Glicoproteínas/genética , Glicoproteínas/inmunología , Humanos , Inmunización , Pulmón/inmunología , Pulmón/microbiología , Masculino , Ratones , Ratones Endogámicos BALB C , Paracoccidioides/patogenicidad , Paracoccidioidomicosis/inmunología , Paracoccidioidomicosis/microbiología , Péptidos/síntesis química , Péptidos/genética , Péptidos/inmunología , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/inmunología , Proteínas Recombinantes de Fusión/metabolismo , Salmonella enterica/genética , Salmonella enterica/inmunología , Salmonella enterica/metabolismoRESUMEN
Recombinant Bacillus subtilis strains, either spores or vegetative cells, may be employed as safe and low cost orally delivered live vaccine vehicles. In this study, we report the use of an orally delivered B. subtilis vaccine strain to boost systemic and secreted antibody responses in mice i.m. primed with a DNA vaccine encoding the structural subunit (CfaB) of the CFA/I fimbriae encoded by enterotoxigenic Escherichia coli (ETEC), an important etiological agent of diarrhea among travelers and children living in endemic regions. DBA/2 female mice submitted to the prime-boost immunization regimen developed synergic serum (IgG) and mucosal (IgA) antibody responses to the target CfaB antigen. Moreover, in contrast to mice immunized only with one vaccine formulation, sera harvested from prime-boosted vaccinated individuals inhibited adhesion of ETEC cells to human red blood cells. Additionally, vaccinated dams conferred full passive protection to suckling newborn mice challenged with a virulent ETEC strain. Taken together the present results further demonstrate the potential use of recombinant B. subtilis strains as an alternative live vaccine vehicle.
Asunto(s)
Anticuerpos Antibacterianos/sangre , Bacillus subtilis/inmunología , Vacunas Bacterianas/inmunología , Sistemas de Liberación de Medicamentos , Escherichia coli Enterotoxigénica/inmunología , Proteínas Fimbrias/inmunología , Vacunas de ADN/inmunología , Administración Oral , Animales , Bacillus subtilis/genética , Escherichia coli Enterotoxigénica/genética , Femenino , Proteínas Fimbrias/genética , Regulación Bacteriana de la Expresión Génica , Humanos , Inmunización , Infusiones Parenterales , Ratones , Ratones Endogámicos DBA , Regiones Promotoras Genéticas/genética , Proteínas Recombinantes/inmunología , Análisis de Supervivencia , Vacunas de ADN/administración & dosificaciónRESUMEN
The currently available anti-pneumococcal vaccines are based on capsular polysaccharide (PS), plain or conjugated to a carrier protein. Conjugated vaccines are expensive products, especially in the case of pneumococcus, in which reasonable coverage requires from 7 to 13 serotypes. To obtain increased coverage with fewer components, we evaluated the immunogenicity of the pneumococcal surface protein A (PspA), conjugated to capsular polysaccharide serotype 23F, aiming at induction of an immune response against both components. Mice immunized with PS23F-rPspA1 conjugate produced antibodies against both PS and rPspA1, comparable or slightly higher than that obtained by free PS. The immunized animals challenged with a lethal dose of a virulent strain bearing a homologous PspA, showed that the PS23F-rPspA1 conjugate induced higher survival than rPspA1 alone or in combination with PS. This increased protection was shown to correlate with the enhanced capacity of the antibodies to bind to the pneumococcal surface and to induce complement deposition. Our results indicate that the use of PS-PspA conjugates may be a way to increase coverage against pneumococci with fewer components.
Asunto(s)
Proteínas Bacterianas/inmunología , Vacunas Neumococicas/inmunología , Vacunas Neumococicas/uso terapéutico , Polisacáridos/inmunología , Polisacáridos/uso terapéutico , Animales , Anticuerpos Antibacterianos/análisis , Anticuerpos Antibacterianos/biosíntesis , Proteínas del Sistema Complemento/biosíntesis , Ensayo de Inmunoadsorción Enzimática , Femenino , Ratones , Ratones Endogámicos BALB C , Vacunas Conjugadas/inmunología , Vacunas Conjugadas/uso terapéutico , Vacunas Sintéticas/inmunología , Vacunas Sintéticas/uso terapéuticoRESUMEN
The currently available anti-pneumococcal vaccines are based on capsular polysaccharide (PS), plain or conjugated to a carrier protein. Conjugated vaccines are expensive products, especially in the case of pneumococcus, in which reasonable coverage requires from 7 to 13 serotypes. To obtain increased coverage with fewer components, we evaluated the immunogenicity of the pneumococcal surface protein A (PspA), conjugated to capsular polysaccharide serotype 23F, aiming at induction of an immune response against both components. Mice immunized with PS23F-rPspA1 conjugate produced antibodies against both PS and rPspA1, comparable or slightly higher than that obtained by free PS. The immunized animals challenged with a lethal dose of a virulent strain bearing a homologous PspA, showed that the PS23F-rPspA1 conjugate induced higher survival than rPspA1 alone or in combination with PS. This increased protection was shown to correlate with the enhanced capacity of the antibodies to bind to the pneumococcal surface and to induce complement deposition. Our results indicate that the use of PS-PspA conjugates may be a way to increase coverage against pneumococci with fewer components.
Asunto(s)
Humanos , Streptococcus pneumoniae/clasificación , Streptococcus pneumoniae/inmunología , Vacunas Conjugadas/clasificación , Vacunas NeumococicasRESUMEN
Recombinant Bacillus subtilis strains, either spores or vegetative cells, may be employed as safe and low cost orally delivered live vaccine vehicles. In this study, we report the use of an orally delivered B. subtilis vaccine strain to boost systemic and secreted antibody responses in mice i.m. primed with a DNA vaccine encoding the structural subunit (CfaB) of the CFA/I fimbriae encoded by enterotoxigenic Escherichia coli (ETEC), an important etiological agent of diarrhea among travelers and children living in endemic regions. DBA/2 female mice submitted to the prime-boost immunization regimen developed synergic serum (IgG) and mucosal (IgA) antibody responses to the target CfaB antigen. Moreover, in contrast to mice immunized only with one vaccine formulation, sera harvested from prime-boosted vaccinated individuals inhibited adhesion of ETEC cells to human red blood cells. Additionally, vaccinated dams conferred full passive protection to suckling newborn mice challenged with a virulent ETEC strain. Taken together the present results further demonstrate the potential use of recombinant B. subtilis strains as an alternative live vaccine vehicle.
Asunto(s)
Animales , Vacunas contra Escherichia coli/clasificación , Bacillus subtilis , Escherichia coli Enterotoxigénica/genética , Escherichia coli Enterotoxigénica/inmunologíaRESUMEN
Streptococcus pneumoniae is the agent responsible for infections such as pneumonia, otitis media, and meningitis. Among virulence factors, the Pneumococcal surface protein A (PspA) has been shown to be immunogenic and protective in mice, and is thus a good vaccine candidate. PspA has been classified into 6 clades and 3 families. Initially, pspA fragments, clades 1 and 3, were cloned into the pAE-6His expression vector. Proteins were expressed in Escherichia coli BL21(DE3) and purified by affinity and anion exchange chromatographies, with a yield of 11 mg/l of culture. Due to plasmid instability in E. coli, another construct using pspA1 was obtained based on pET-37b(+), which was shown to be stable in E. coli and increased the yield approximately 3-fold. Our results show good conditions for scale-up. Sera from immunized mice recognized PspA in total extracts of S. pneumoniae strains: anti-rPspA1p sera recognized native PspA clades 1 (+++), 2 (++) and 4 (+) and anti-rPspA3p sera recognized PspA clades 1 (+), 2 (+), 3 (+++) and 4 (+). The cross-reactivity pattern obtained confirms the notion that proteins from both families should be included for development of a broad-coverage vaccine; lower-cross reactivity between rPspAs of family 2 indicates that it may be necessary to include 2 proteins from this family.
Asunto(s)
Anticuerpos Antibacterianos/sangre , Anticuerpos Antibacterianos/inmunología , Proteínas Bacterianas/inmunología , Proteínas Bacterianas/metabolismo , Streptococcus pneumoniae/inmunología , Streptococcus pneumoniae/metabolismo , Animales , Proteínas Bacterianas/genética , Reacciones Cruzadas/inmunología , Expresión Génica , Vectores Genéticos/genética , Ratones , Ratones Endogámicos BALB C , Proteínas Recombinantes/genética , Proteínas Recombinantes/inmunología , Proteínas Recombinantes/aislamiento & purificación , Proteínas Recombinantes/metabolismo , Streptococcus pneumoniae/genética , Streptococcus pneumoniae/aislamiento & purificaciónRESUMEN
Recombinant Bacillus subtilis strains, either in the form of spores or vegetative cells, may be employed as safe and low-cost vaccine vehicles. In this study, we studied the role of promoter sequences and antigen-sorting signals on the immunogenicity based on previously constructed B. subtilis episomal expression systems. Mice orally immunized with spores or cells encoding the B subunit of the heat labile toxin (LTB), originally expressed by some enterotoxigenic Escherichia coli (ETEC) strains, under control of the stress-inducible gsiB promoter developed higher anti-LTB serum IgG and fecal IgA responses with regard to vaccine strains transformed with plasmids encoding the antigen under control of IPTG-inducible (Pspac) or constitutive (PlepA) promoters. Moreover, surface expression of the vaccine antigen under the control of the PgsiB promoter enhanced the immunogenicity of vegetative cells, while intracellular accumulation of LTB led to higher antibody responses in mice orally immunized with recombinant B. subtilis spores. Specific anti-LTB antibodies raised in vaccinated mice recognized and neutralized in vitro the native toxin produced by ETEC strains. Nonetheless, only mice orally immunized with recombinant B. subtilis strains, either as vegetative cells or spores, expressing intracellular LTB under the control of the gsiB promoter conferred partial protection to lethal challenges with purified LT. The present report further demonstrates that B. subtilis plasmid-based heterologous protein expression systems are adequate for antigen delivery via the oral route.
Asunto(s)
Bacillus subtilis/inmunología , Toxinas Bacterianas/biosíntesis , Toxinas Bacterianas/metabolismo , Vacunas Bacterianas/inmunología , Enterotoxinas/biosíntesis , Enterotoxinas/metabolismo , Proteínas de Escherichia coli/biosíntesis , Proteínas de Escherichia coli/metabolismo , Regiones Promotoras Genéticas , Señales de Clasificación de Proteína/genética , Administración Oral , Animales , Anticuerpos Antibacterianos/análisis , Anticuerpos Antibacterianos/sangre , Antígenos Bacterianos/biosíntesis , Antígenos Bacterianos/inmunología , Antígenos Bacterianos/metabolismo , Antitoxinas/análisis , Antitoxinas/sangre , Bacillus subtilis/genética , Proteínas Bacterianas/genética , Toxinas Bacterianas/inmunología , Vacunas Bacterianas/administración & dosificación , Vacunas Bacterianas/genética , Modelos Animales de Enfermedad , Enterotoxinas/inmunología , Escherichia coli/genética , Proteínas de Escherichia coli/inmunología , Femenino , Inmunoglobulina A/análisis , Inmunoglobulina G/sangre , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Pruebas de Neutralización , Plásmidos/genética , Intoxicación/inmunología , Subunidades de Proteína/biosíntesis , Subunidades de Proteína/inmunología , Subunidades de Proteína/metabolismo , Proteínas Recombinantes/biosíntesis , Proteínas Recombinantes/inmunología , Proteínas Recombinantes/metabolismo , Esporas Bacterianas/inmunología , Análisis de SupervivenciaRESUMEN
Bacillus subtilis has been successfully engineered to express heterologous antigens genetically fused to surface-exposed spore coat proteins as a vaccine vehicle endowed with remarkable heat resistance and probiotic effects for both humans and animals. Nonetheless, the immunogenicity of passenger antigens expressed by B. subtilis spores is low particularly following oral delivery. In this work, we describe a new episomal expression system promoting enhanced immunogenicity of heterologous antigens carried by B. subtilis strains, either in the form of spores or vegetative cells, following oral or parenteral delivery to mice. Based on a bi-directional replicating multicopy plasmid, the gene encoding the B subunit of the heat-labile toxin (LTB), produced by enterotoxigenic Escherichia coli (ETEC) strains, was cloned under the control of the B. subtilis glucose starvation inducible (gsiB) gene promoter, active in vegetative cells submitted to heat and other stress conditions. The recombinant plasmid proved to be structurally and segregationally stable in both cells and spores under in vitro and in vivo conditions. Moreover, BALB/c mice orally immunized with B. subtilis cells or spores elicited enhanced anti-LTB systemic (serum IgG) and secreted (fecal IgA) antibody responses, thus, suggesting that antigen expression occurred during in vivo transit. These results indicate that the new episomal expression system may improve the performance of B. subtilis as a live orally-delivered vaccine carrier.
Asunto(s)
Bacillus subtilis/genética , Proteínas Bacterianas/genética , Toxinas Bacterianas/inmunología , Vacunas Bacterianas/inmunología , Enterotoxinas/inmunología , Proteínas de Escherichia coli/inmunología , Regulación Bacteriana de la Expresión Génica , Vectores Genéticos , Regiones Promotoras Genéticas , Administración Oral , Animales , Anticuerpos Antibacterianos/sangre , Bacillus subtilis/inmunología , Toxinas Bacterianas/genética , Vacunas Bacterianas/administración & dosificación , Vacunas Bacterianas/genética , Enterotoxinas/genética , Ensayo de Inmunoadsorción Enzimática , Proteínas de Escherichia coli/genética , Heces/química , Femenino , Inmunoglobulina A/análisis , Inmunoglobulina G/sangre , Inyecciones Intraperitoneales , Ratones , Ratones Endogámicos C57BL , Plásmidos/genética , Vacunas Sintéticas/administración & dosificación , Vacunas Sintéticas/genética , Vacunas Sintéticas/inmunologíaRESUMEN
Bacillus subtilis has been successfully engineered to express heterologous antigens genetically fused to surface-exposed spore coat proteins asa vaccine vehicle endowed with remarkable heat resistance and probiotic effects for both humans and animals. Nonetheless, the immunogenicityof passenger antigens expressed by B. subtilis spores is low particularly following oral delivery. In this work, we describe a new episomalexpression system promoting enhanced immunogenicity of heterologous antigens carried by B. subtilis strains, either in the form of sporesor vegetative cells, following oral or parenteral delivery to mice. Based on a bi-directional replicating multicopy plasmid, the gene encodingthe B subunit of the heat-labile toxin (LTB), produced by enterotoxigenic Escherichia coli (ETEC) strains, was cloned under the controlof the B. subtilis glucose starvation inducible (gsiB) gene promoter, active in vegetative cells submitted to heat and other stress conditions.The recombinant plasmid proved to be structurally and segregationally stable in both cells and spores under in vitro and in vivo conditions.Moreover, BALB/c mice orally immunized with B. subtilis cells or spores elicited enhanced anti-LTB systemic (serum IgG) and secreted(fecal IgA) antibody responses, thus, suggesting that antigen expression occurred during in vivo transit. These results indicate that the newepisomal expression system may improve the performance of B. subtilis as a live orally-delivered vaccine carrier.
Asunto(s)
Humanos , Escherichia coli Enterotoxigénica/inmunología , Vacunas/inmunologíaRESUMEN
Repeated evidence has demonstrated that combined primer-booster immunization regimens can improve both secreted and humoral immune responses to antigens derived from viral, bacterial, and parasitic pathogens. For the present work, we evaluated the synergic serum immunoglobulin G (IgG) and fecal IgA antibody responses elicited in BALB/c mice who were intramuscularly primed with a DNA vaccine, pRECFA, followed by oral boosting with an attenuated Salmonella enterica serovar Typhimurium vaccine (HG3) strain, with both vaccines encoding the structural subunit (CfaB) of the CFA/I fimbriae produced by human-derived enterotoxigenic Escherichia coli (ETEC) strains. The immunological properties of the vaccine regimen were evaluated according to the order of the administered vaccines, the nature of the oral antigen carrier, the age of the vaccinated animals, the interval between the priming and boosting doses, and the amount of injected DNA. The production of gamma interferon and the IgG2a subclass in serum indicated that mice immunized with the primer-booster regimen developed prevailing type 1 T-cell-dependent immune responses. The synergic effect of the vaccine regimen on the induced antibody responses was also revealed by its ability to block the adhesive properties of CFA/I fimbriae expressed by live bacteria, as shown by the inhibition of Caco-2 cell and human erythrocyte binding. Moreover, DBA2 newborn mice were protected from lethal challenges with a CFA/I+ ETEC strain after the incubation of live bacteria with serum samples harvested from mice who were subjected to the primer-booster regimen. We propose, therefore, that the DNA primer-Salmonella booster regimen represents an alternative for the development of vaccines requiring both mucosal and systemic antibody responses for immunological protection.